Tirzepatide GLP1 & GIP

Tirzepatide is the active ingredient found in the brand-name medications Mounjaro™ and Zepbound™. Tirzepatide combines a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor, both of which are found in areas of the brain that regulate appetite. 

While every individual responds differently to medications, a medical study of 783 participants demonstrated that in a 88-week period, participants lost an average body weight of ~26.6%. 

• Adults with a BMI of 27 or more (obesity category). 
• Adults with a BMI of 27-29 (overweight category), who also have at least one weight-related comorbid condition such as hypertension, diabetes type 2, or hyperlipidedemia

Tirzepatide can be administered weekly, at any time of day but on the same day each week, with or without meals. 

Tirzepatide should be injected subcutaneously into upper arms, abdomen or thighs. 

If there is a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in case of hypersensitivity to Tirzepatide

The most common side effects of Tirzepatide include nausea, diarrhea/constipation, feeling bloated, heartburn, belching, dizziness, vomiting, and upset stomach. 

Tirzepatide is dispensed by our contracted pharmacy. Current delivery time is 5-7 business days approximately. 

To schedule a Telehealth or in-office visit, you can click on the Book An Appointment tab, or call us Toll-Free (866) 322-3775